Triple Immune Checkpoint Blockade Tested in Advanced Solid Tumors
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Summary
This Bristol-Myers Squibb-sponsored trial tested lirilumab, an antibody that blocks KIR receptors on natural killer cells, in combination with nivolumab (anti-PD-1) and optionally ipilimumab (anti-CTLA-4) in patients with advanced, treatment-refractory solid tumors. The goal was to determine whether simultaneously releasing multiple immune brakes could produce stronger cancer-killing responses than existing checkpoint inhibitor combinations. The study assessed safety, tolerability, dose-limiting toxicities, and maximum tolerated dose in Phase 1, then evaluated preliminary anti-tumor activity in Phase 2. By targeting both the innate immune system (via KIR/NK cells) and adaptive immune system (via T cells), the trial represented an early attempt at multi-layered immune activation. Results from this completed trial may inform future combination immunotherapy strategies for patients who have failed standard treatments.
Detailed Summary
Checkpoint inhibitor combinations have transformed oncology, but many patients with advanced solid tumors still fail to respond or eventually relapse. Researchers sought to determine whether adding a third immune checkpoint blockade — targeting KIR receptors on natural killer (NK) cells — could meaningfully enhance anti-tumor immunity beyond what PD-1 and CTLA-4 inhibitors achieve alone.
This Phase 1/2 trial, sponsored by Bristol-Myers Squibb and initiated in 2012, enrolled patients with metastatic or unresectable refractory solid tumors. Participants received lirilumab (an anti-KIR antibody) combined with nivolumab (anti-PD-1), with a subset also receiving ipilimumab (anti-CTLA-4). Phase 1 focused on establishing safety, identifying dose-limiting toxicities, and determining the maximum tolerated dose. Phase 2 assessed preliminary anti-tumor activity across these combinations.
The scientific rationale was compelling: KIR receptors suppress NK cell cytotoxicity, PD-1 dampens T cell responses, and CTLA-4 limits early T cell activation. Blocking all three pathways simultaneously was hypothesized to produce synergistic immune activation. This multi-arm design allowed direct comparison of dual versus triple checkpoint blockade strategies.
The trial has since been completed, though detailed efficacy and safety outcomes are not available from the abstract alone. The combination strategy represented an important step in understanding whether innate and adaptive immune arms could be co-targeted safely and effectively in humans. Results from this study have contributed to the broader understanding of NK cell biology in cancer immunotherapy.
Caveats are significant: this summary is based solely on the trial registration abstract, so specific outcomes, response rates, and toxicity profiles cannot be reported. The patient population was heavily pre-treated and heterogeneous, limiting generalizability. Nonetheless, this trial helped pioneer the concept of innate-plus-adaptive immune checkpoint combination therapy in solid tumors.
Key Findings
- Trial tested simultaneous blockade of KIR, PD-1, and CTLA-4 immune checkpoints in refractory solid tumors.
- Phase 1 aimed to establish maximum tolerated dose of lirilumab plus nivolumab combination.
- Phase 2 evaluated preliminary anti-tumor activity of dual and triple checkpoint combinations.
- Study targeted both innate (NK cells via KIR) and adaptive (T cells via PD-1/CTLA-4) immunity.
- Trial is completed, representing an early clinical test of NK cell-inclusive combination immunotherapy.
Methodology
This was a Phase 1/2 open-label trial enrolling adults with advanced, metastatic, or unresectable refractory solid tumors. Phase 1 used dose-escalation design to identify DLTs and MTD; Phase 2 assessed anti-tumor activity. Multiple arms compared lirilumab plus nivolumab versus lirilumab plus nivolumab plus ipilimumab.
Study Limitations
This summary is based on the trial registration abstract only — full results, including response rates, survival outcomes, and detailed toxicity data, are not available and cannot be reported. The heavily pre-treated, heterogeneous solid tumor population limits generalizability of any efficacy findings. As a Phase 1/2 trial, the study was not powered for definitive efficacy conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.